MedPath

Averitas Pharma, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:4
Completed:0

Trial Phases

2 Phases

Phase 1:3
Phase 3:2

Drug Approvals

1

FDA:1

Drug Approvals

Qutenza

Approval Date
Mar 28, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 3
2 (40.0%)

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Not yet recruiting
Conditions
Peripheral Diabetic Neuropathy
Painful Diabetic Neuropathy
Interventions
First Posted Date
2024-07-10
Last Posted Date
2025-03-26
Lead Sponsor
Averitas Pharma, Inc.
Target Recruit Count
150
Registration Number
NCT06495424

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Phase 3
Active, not recruiting
Conditions
Post Surgical Neuropathic Pain
Interventions
First Posted Date
2021-07-19
Last Posted Date
2025-07-23
Lead Sponsor
Averitas Pharma, Inc.
Target Recruit Count
409
Registration Number
NCT04967664
Locations
🇺🇸

Tucson Orthopaedic Institute, Tucson, Arizona, United States

🇺🇸

UCSD Center for Pain Medicine, La Jolla, California, United States

🇺🇸

ILD Research Center, Vista, California, United States

and more 61 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.